---
title: "Citius Pharmaceuticals Amends Promissory Note to Enhance Flexibility"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285780539.md"
description: "Citius Pharmaceuticals has amended a $3.8 million promissory note to enhance flexibility. The repayment is now deferred until 91 days after Citius Oncology's senior debt is fully repaid, with prior maturity triggers removed. A voluntary conversion feature allows conversion of principal into common stock at $0.90 per share. Analysts rate CTXR stock as a Buy with a $6.00 price target, though Spark's AI Analyst gives it a Neutral score due to weak financial performance and bearish momentum. Citius focuses on developing cancer therapies through equity and debt financing."
datetime: "2026-05-08T22:05:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285780539.md)
  - [en](https://longbridge.com/en/news/285780539.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285780539.md)
---

# Citius Pharmaceuticals Amends Promissory Note to Enhance Flexibility

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Citius Pharmaceuticals ( (CTXR) ) just unveiled an update.

On May 4, 2026, Citius Pharmaceuticals and its majority-owned unit Citius Oncology amended a 2024 promissory note originally issued by Citius Oncology to the parent in the principal amount of about $3.8 million, aligning its payment and maturity terms with a new debt facility. Under the Third Amendment, repayment is deferred until 91 days after Citius Oncology’s senior debt is fully repaid and its loan agreement terminated, prior maturity triggers tied to capital raises or security issuances are removed, cash prepayment is barred before the new maturity date, and a voluntary conversion feature is added that allows Citius Pharmaceuticals, with Citius Oncology’s consent, to convert principal into common stock at $0.90 per share, enhancing capital structure flexibility for both entities.

The most recent analyst rating on (CTXR) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Citius Pharmaceuticals stock, see the CTXR Stock Forecast page.

**Spark’s Take on CTXR Stock**

According to Spark, TipRanks’ AI Analyst, CTXR is a Neutral.

The score is held back primarily by weak financial performance (large ongoing losses and significant cash burn) and bearish technical momentum (below major moving averages with negative MACD). Offsetting factors include a low-debt balance sheet and notably positive corporate updates around LYMPHIR’s commercial rollout and early-stage expansion signals.

To see Spark’s full report on CTXR stock, click here.

**More about Citius Pharmaceuticals**

Citius Pharmaceuticals, Inc. is a biopharmaceutical company with a majority-owned oncology subsidiary, Citius Oncology, Inc., focused on developing and financing cancer-related therapies. The group utilizes a mix of equity financings and debt facilities to fund its operations and advance its oncology pipeline within the competitive cancer therapeutics market.

**Average Trading Volume:** 723,260

**Technical Sentiment Signal:** Strong Sell

**Current Market Cap:** $17.73M

See more insights into CTXR stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [CTXR.US](https://longbridge.com/en/quote/CTXR.US.md)
- [CTOR.US](https://longbridge.com/en/quote/CTOR.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)

## Related News & Research

- [ImmunityBio faces securities class action after FDA flags misleading Anktiva cancer claims](https://longbridge.com/en/news/287226578.md)
- [Ontada Integrates Florida Cancer Specialists & Research Institute Data to Enrich Its Data Ecosystem](https://longbridge.com/en/news/287218916.md)
- [08:03 ETNCCN reafirma su compromiso con los recursos para el manejo del malestar relacionado con el cáncer](https://longbridge.com/en/news/287060831.md)
- [How Chubb’s (CB) New Canada Cancer Coverage Launch Could Reframe Its Health Benefits Strategy](https://longbridge.com/en/news/286787301.md)
- [Health Rounds: Widely used asthma drug may improve performance of cancer immunotherapies](https://longbridge.com/en/news/286957357.md)